Login to Your Account

Genzyme's 2Q Earnings Mask ILEX Merger; Stock Moves Up

By Aaron Lorenzo

Thursday, July 15, 2004
Strong sales and earnings propelled Genzyme Corp.'s second-quarter results past estimates and led the company to forecast continued growth that would offset any dilution related to its merger with ILEX Oncology Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription